Growth Hormone in Poor Responders to IVF Trial

Infertility Clinical Trial

Official title:

Adjuvant Growth Hormone in Infertile Women With Prior Poor IVF Response: a Randomized, Controlled, Open-label Study

Clinical Trial Details — Status: Terminated

Administrative data

• NCT number: NCT01616225
• Other study ID #: PCRM-001
• Status: Terminated
• Phase: Phase 2/Phase 3
• First received: April 10, 2012
• Last updated: July 22, 2014
• Start date: June 2012
• Est. completion date: August 2015

Study information

• Verified date: July 2014
• Source: Pacific Centre for Reproductive Medicine
• Contact: n/a
• Is FDA regulated: No
• Health authority: Health Canada: Health Products and Food Branch
• Study type: Interventional

Clinical Trial Summary

This study (the "Adjuvant Growth Hormone Study") is being done to see the effects of adding Growth Hormone (GH) during fertility treatment (also called in vitro fertilization or IVF). Growth Hormone is a protein that your body normally produces. Growth Hormone can act on several different organs, including the ovaries, where eggs are made. From evidence gathered from studies done by fertility doctors over the years, researchers believe that women who have not become pregnant through IVF in the past might have better results if they go on a course of Growth Hormone during the IVF treatment. However, more research needs to be done to confirm whether adding Growth Hormone is beneficial and also to find out the best time to start Growth Hormone treatment during IVF.

We hope that our Adjuvant Growth Hormone study will help answer these questions.

Recruitment information / eligibility

• Status: Terminated
• Enrollment: 60
• Est. completion date: August 2015
• Est. primary completion date: June 2015
• Accepts healthy volunteers: No
• Gender: Female
• Age group: 18 Years to 44 Years

Eligibility

Inclusion Criteria:

• Subject with prior poor response(s) to ovarian stimulation for IVF or ICSI. Poor response is defined as a history of producing fewer than four follicles =14 mm in diameter during previous COS cycles where FSH or HMG was used from cycle start at a daily dose of =450 IU

• Age = 45 years

• Baseline blood labs, measured within previous month, show fasting blood glucose <6.1 mmol/L and TSH = 5.5 mU/L

• Early follicular phase (Day 2 or Day 3) serum FSH, evaluated in the preceding 6 months

• Subject willing and able to give informed consent

Exclusion Criteria:

• Concurrently enrolled in any other clinical trial

• Previous participation in this study

• Using GnRH agonist in COS protocol

• Any prior early follicular phase serum FSH level =12 IU/L

• Use of any of the following is contraindicated or inappropriate: GH, Cetrotide®, FSH, LH or hCG

• Used OCP within the prior month

• Pregnant or lactating

• Untreated hydrosalpinx

• Tobacco smoker

• Diabetic or otherwise at risk of gestational diabetes

• BMI > 38 kg/m2

• Poorly controlled thyroid disease

• Known cancer or prior history of malignancies

Study Design

Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment

Related Conditions & MeSH terms

• Infertility

Intervention

Drug:
• Saizen (Human Growth Hormone)
Subjects will receive the standard protocol treatment, as well as adjuvant GH. One 3.33 mg vial Human Growth Hormone(10 IU Saizen®) will be self-administered daily by subcutaneous injection. GH treatment will start 14 days before FSH start and will continue until the day of the HCG treatment.
• Saizen (Human Growth Hormone)
Subjects will receive the standard IVF treatment, as well as adjuvant GH as above. One 3.33 mg vial Human Growth Hormone(10 IU Saizen®) will be self-administered daily by subcutaneous injection. GH treatment will start on the same day as the FSH start and will continue until the day of HCG treatment.
• No Saizen Control (Standard IVF Protocol)
All patients will be administered an oral contraceptive (Marvelon®). FSH treatment (daily subcutaneous injections of 450 IU Gonal-F®; Serono Canada) must begin 4 days after OCP stop, providing both of the following criteria are met. Pituitary downregulation with GnRH antagonist (Cetrotide®, Serono Canada) 0.25mg daily (subcutaneous injection) and LH (Luveris®, Serono Canada) 75 IU daily (subcutaneous injection) will be initiated when one or both of the following criteria are satisfied. Monitoring will continue until a lead follicle reaches =18 mm, at which time HCG (Ovidrel®, Serono Canada) 250 mcg will be administered by subcutaneous injection. Oocytes will be retrieved 36 hours after HCG treatment. Luteal support for the endometrium (90 mg progesterone (8% progesterone gel; Crinone® gel), administered intravaginally once daily) will begin one day after oocyte retrieval and will be maintained at least until day 31 of gestation.

Locations

Country	Name	City	State
Canada	Pacific Centre for Reproductive Medicine	Burnaby	British Columbia

Sponsors (2)

Lead Sponsor	Collaborator
Pacific Centre for Reproductive Medicine	EMD Serono

Country where clinical trial is conducted

Canada, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Oocyte yield	To assess the effect of adjuvant GH on the number of mature oocytes recovered from women undergoing COS using a GnRH antagonist protocol.	Following course of treatment (2-3 weeks)	No
Secondary	Pregnancy rate	To assess the effect of adjuvant GH on: the proportion of subjects reaching embryo transfer; embryo quality; implantation rate; clinical pregnancy rate evaluated 5 weeks after IVF/ICSI (week 7 of gestation); proportion of subjects with clinical pregnancy; mean (SD) crown-rump length 5 weeks after IVF/ICSI (week 7 of gestation); proportion of subjects with a viable fetus(es) at week 12 of gestation; proportion of subjects with live births; duration of FSH stimulation; ampules of FSH consumed; and safety.	Approximately 2 weeks following completion of treatment.	No